ANDA 91601, held by Tris Pharma. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 91601 (Methylphenidate Hydrochloride), held by Tris Pharma, was first approved by FDA on Jul 23, 2010, with 6 approved supplements and 0 published complete response letters.
Methylphenidate hydrochloride oral solution is indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 23, 2010 | Original application | Approved |
| Methylphenidate Hydrochloride5MG/5ML · solution;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride10MG/5ML · solution;oral | Methylphenidate Hydrochloride | Rx |
| May 13, 2024 | Supplement 14Labeling · Standard review | Approved | None posted |
| Sep 6, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 6, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 6, 2022 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 6, 2022 | Supplement 10Labeling · Standard review | Approved | None posted |
| Sep 19, 2013 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 23, 2010 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters